New South Korean Study On NVX-COV2373 Heterologous Booster Shows Higher Neutralizing Antibody Titers Than Pfizer-BNT Bivalent Booster For Omicron BA.5 Variant
A new South Korean study on NVX-COV2373 heterologous booster shots, funded by Korea Disease Control and Prevention Agency (South Korean equivalent of US CDC) and SK Bioscience shows higher neutralizing antibody titers than Pfizer-BNT Bivalent booster shots (as shown in a Pfizer presentation to CDC), for the currently dominant Omicron BA.5 Variant, as can be seen in the picture below.
NVX-COV2373 Heterologous Booster & Pfizer-BNT Bivalent Booster nAb GMT Comparison
What else does US FDA need to authorize the NVAX booster shots? This should also hopefully go a long way in convincing health regulatory agencies in other countries like Australia and UK to authorize these shots as boosters.
Glad I sold at $36 amidst being down 70%. I read an article on seeking alpha 2-3 months back stating this will go to $20 and I didn’t believe it. Well here we are, I think it’s headed for 15 and then 10 or lower. Their outlook and sales will be even worse.